Cognex (NASDAQ:CGNX) Downgraded to Hold Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Cognex from “buy” to “hold,” although broader analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $75.85.
• Cognex reported quarterly EPS of $0.45, ahead of the $0.42 estimate, while revenue rose 16.9% year over year to $291.26 million. The company issued fiscal 2026 EPS guidance of $1.64–$1.68, above the $1.48 analyst consensus.
• Insiders have been significant sellers: company insiders sold 224,847 shares worth roughly $15 million over the past 90 days, while institutional investors own 88.12% of the stock.

Cognex (NASDAQ:CGNX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently weighed in on the stock. Zacks Research raised shares of Cognex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, June 16th. Cantor Fitzgerald increased their price objective on shares of Cognex from $76.00 to $84.00 and gave the stock an "overweight" rating in a research note on Friday. Citigroup reissued a "neutral" rating and issued a $74.00 target price (up from $72.00) on shares of Cognex in a report on Friday. DA Davidson set a $62.00 target price on Cognex and gave the company a "neutral" rating in a report on Thursday, May 14th. Finally, UBS Group set a $75.00 price target on Cognex in a report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $75.85.

Cognex Trading Down 0.7%

Shares of CGNX opened at $66.89 on Friday. Cognex has a 52 week low of $34.60 and a 52 week high of $72.88. The firm has a market cap of $11.13 billion, a price-to-earnings ratio of 64.94 and a beta of 1.49. The stock has a 50 day moving average of $65.01 and a 200-day moving average of $57.16.

Cognex (NASDAQ:CGNX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The scientific and technical instruments company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. Cognex had a return on equity of 13.50% and a net margin of 16.05%.The firm had revenue of $291.26 million for the quarter, compared to analysts' expectations of $292.10 million. During the same period last year, the business posted $0.25 earnings per share. The firm's revenue for the quarter was up 16.9% on a year-over-year basis. Cognex has set its FY 2026 guidance at 1.640-1.680 EPS and its Q3 2026 guidance at 0.500-0.540 EPS. On average, sell-side analysts predict that Cognex will post 1.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Cognex news, VP Laura Ann Macdonald sold 98,122 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $66.80, for a total value of $6,554,549.60. Following the sale, the vice president owned 5,258 shares in the company, valued at approximately $351,234.40. This trade represents a 94.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Fennell sold 64,873 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $67.05, for a total transaction of $4,349,734.65. Following the completion of the sale, the insider owned 11,263 shares in the company, valued at $755,184.15. The trade was a 85.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 224,847 shares of company stock worth $14,975,098. Insiders own 1.70% of the company's stock.

Institutional Trading of Cognex

Several hedge funds have recently added to or reduced their stakes in CGNX. Royal Bank of Canada grew its stake in shares of Cognex by 13.2% in the first quarter. Royal Bank of Canada now owns 200,351 shares of the scientific and technical instruments company's stock worth $5,976,000 after purchasing an additional 23,326 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Cognex during the first quarter valued at about $291,000. Intech Investment Management LLC lifted its holdings in Cognex by 24.1% in the first quarter. Intech Investment Management LLC now owns 47,444 shares of the scientific and technical instruments company's stock worth $1,415,000 after purchasing an additional 9,223 shares during the period. Geneos Wealth Management Inc. lifted its holdings in Cognex by 402.2% in the first quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company's stock worth $27,000 after purchasing an additional 736 shares during the period. Finally, Cetera Investment Advisers grew its position in Cognex by 7.5% in the 2nd quarter. Cetera Investment Advisers now owns 13,208 shares of the scientific and technical instruments company's stock valued at $419,000 after buying an additional 920 shares in the last quarter. Institutional investors own 88.12% of the company's stock.

Key Cognex News

Here are the key news stories impacting Cognex this week:

• Positive Sentiment: Strong earnings and raised guidance: Cognex reported adjusted EPS of $0.45, exceeding the $0.42 consensus and rising from $0.25 a year ago. Revenue reached a record $291 million, up 16.9% year over year, while margin improvement, favorable product mix and cost controls boosted profitability. The company raised full-year 2026 adjusted EPS guidance to $1.64–$1.68, versus the $1.48 consensus, and projected third-quarter EPS of $0.50–$0.54. Cognex Q2 Earnings Beat on Margin Gains Despite Revenue Miss
• Positive Sentiment: Growth opportunities are broadening: Management highlighted AI-enabled machine vision, data-center expansion and increasing business with existing customers as growth drivers. Investors are also encouraged by strength across most major end markets and improving margins. Cognex Q2 Earnings Call Centers on AI and Data Center Growth
• Positive Sentiment: Analyst targets moved higher: Cantor Fitzgerald raised its target to $84 and assigned an overweight rating, Needham lifted its target to $80 with a buy rating, and Truist increased its target to $78 while maintaining a hold rating. The revisions signal greater confidence in Cognex’s earnings trajectory. Analyst price-target updates
• Neutral Sentiment: Revenue modestly missed estimates: Quarterly revenue of approximately $291 million was slightly below the $292.1 million consensus, but the shortfall was offset by stronger margins and earnings. Cognex misses Q2 revenue estimates
• Negative Sentiment: Insider selling may temper enthusiasm: Recent disclosures indicate company insiders made 16 sales and no purchases over the past six months. This does not necessarily indicate deteriorating fundamentals, but it can add a valuation-related overhang.

Cognex Company Profile

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company's product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source